Stock Scorecard
Stock Summary for Exelixis Inc (EXEL) - $23.65 as of 4/25/2024 7:40:53 AM EST
Total Score
13 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for EXEL
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for EXEL
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for EXEL
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for EXEL
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for EXEL
Financial Details for EXEL
Company Overview |
|
|---|---|
| Ticker | EXEL |
| Company Name | Exelixis Inc |
| Country | USA |
| Description | Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California. |
| Sector Name | TRADE & SERVICES |
| Industry Name | SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH |
| Most Recent Quarter | 12/31/2023 |
| Next Earnings Date | 4/30/2024 |
Stock Price History |
|
| Last Day Price | 23.65 |
| Last Day Price Updated | 4/25/2024 7:40:53 AM EST |
| Last Day Volume | 0 |
| Average Daily Volume | 2,208,051 |
| 52-Week High | 24.34 |
| 52-Week Low | 18.08 |
| Last Price to 52 Week Low | 30.81% |
Valuation Measures |
|
| Trailing PE | 36.48 |
| Industry PE | 31.26 |
| Sector PE | 39.28 |
| 5-Year Average PE | 28.69 |
| Free Cash Flow Ratio | 7.00 |
| Industry Free Cash Flow Ratio | 44.75 |
| Sector Free Cash Flow Ratio | 84.41 |
| Current Ratio Most Recent Quarter | 3.34 |
| Total Cash Per Share | 3.38 |
| Book Value Per Share Most Recent Quarter | 7.48 |
| Price to Book Ratio | 3.06 |
| Industry Price to Book Ratio | 8.15 |
| Sector Price to Book Ratio | 8.75 |
| Price to Sales Ratio Twelve Trailing Months | 3.78 |
| Industry Price to Sales Ratio Twelve Trailing Months | 4.00 |
| Sector Price to Sales Ratio Twelve Trailing Months | 1.87 |
Share Statistics |
|
| Total Shares Outstanding | 294,800,000 |
| Market Capitalization | 6,972,020,000 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 2.47% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | -98.60% |
| Annual Earnings Growth | 13.98% |
| Reported EPS 12 Trailing Months | 0.65 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | 0.74 |
| Net Income Twelve Trailing Months | 207,765,000 |
| Net Income Past Year | 207,765,000 |
| Net Income Prior Year | 182,282,000 |
| Quarterly Revenue Growth YOY | 13.10% |
| 5-Year Revenue Growth | 16.47% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 995,302,000 |
| Total Cash Past Year | 995,302,000 |
| Total Cash Prior Year | 1,308,468,000 |
| Net Cash Position Most Recent Quarter | 995,302,000 |
| Net Cash Position Past Year | 995,302,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 2,263,912,000 |
| Total Stockholder Equity Prior Year | 2,488,427,000 |
| Total Stockholder Equity Most Recent Quarter | 2,263,912,000 |
Options |
|
| Put/Call Ratio | 0.39 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.03 |
| MACD Signal | 0.11 |
| 20-Day Bollinger Lower Band | 20.54 |
| 20-Day Bollinger Middle Band | 22.59 |
| 20-Day Bollinger Upper Band | 24.65 |
| Beta | 0.57 |
| RSI | 45.21 |
| 50-Day SMA | 21.34 |
| 200-Day SMA | 20.42 |
System |
|
| Modified | 4/25/2024 12:10:08 AM EST |